Taysha Gene Therapies(TSHA)

Focus: Taysha Gene Therapies is a Dallas-based public biotechnology company focused on developing adeno-associated virus (AAV) gene therapies for rare neurological and genetic disorders. The company is in clinical-stage development with a specialized, high-risk pipeline targeting severe pediatric and neurological indications.

Gene Therapy

Profile data last refreshed 13h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Taysha Gene Therapies

AI assessmentNot Hiring

No open roles listed right now. Follow Taysha Gene Therapies to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$8M

Pipeline & Clinical Trials

None

Leigh Syndrome

N/A

Clinical Trials (1)

NCT05277363A Study of the Natural Course of SURF1 Deficiency

N/A

Help build intelligence for Taysha Gene Therapies

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge AAV gene therapy platform targeting rare neurological diseases with high unmet medical need and potential for transformative impact.
Publicly traded company with $139M cash position (FY 2025) and reaffirmed FDA pathway for lead program TSHA-102 in Rett Syndrome, providing near-term catalysts.
Opportunity to contribute to early-stage drug development across Phase 1/2 and Phase 3 programs in a specialized, focused therapeutic area.

Watch Out For

Severe burn rate: $66M R&D spend on only $8M revenue (FY 2025) with $89.3M net loss indicates limited runway unless clinical success accelerates.
No active job postings currently listed, signaling either full staffing or pause on hiring amid clinical development and financial constraints.
Declining revenue trajectory ($15M FY 2024 → $8M FY 2025) combined with gene therapy regulatory and manufacturing complexity creates execution risk.

Generated by Claude from Taysha Gene Therapies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

TSHA-101

Infantile GM2 Gangliosidosis (Disorder)

PHASE_1_2

Clinical Trials (1)

NCT04798235First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis

Phase 1/2

TSHA-102

Rett Syndrome

PHASE_1_2

Clinical Trials (1)

NCT06152237Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)

Phase 1/2

TSHA-102

Rett Syndrome

PHASE_3

Clinical Trials (2)

NCT07480564Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome

Phase 3

NCT05606614A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Rare Diseases

Publications: 8 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Rare Diseases

3 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$8M46%

R&D Spend

$66M(792%)16%

Net Income

-$89M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(8)

Recent peer-reviewed publications with author affiliations at this company

rAAV9 vector biodistribution in nonhuman primate brain and spinal cord following lumbar intrathecal infusion.

Frontiers in medicine

2026

PMID:42136830

Intrathecal Gene Therapy for Giant Axonal Neuropathy.

The New England journal of medicine

Showing 5 of 8 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Taysha Gene Therapies(TSHA)

About Taysha Gene Therapies

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Taysha Gene Therapies(10)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Research Publications(8)